New pill combo aims to control bile duct cancer when standard care fails

NCT ID NCT07146646

First seen Nov 12, 2025 · Last updated Jun 17, 2026 · Updated 29 times

Summary

This study tests a new combination of two chemotherapy drugs—a pill (trifluridine/tipiracil) plus an IV drug (oxaliplatin)—for people with advanced bile duct or gallbladder cancer whose first treatment stopped working or didn't help. The goal is to see if this combo controls the cancer better than the usual second-line treatment (FOLFOX). About 27 adults will take part, and researchers will measure how many patients' cancer stops growing or shrinks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

biliary tract cancer biliary tract neoplasm Biliary Tract Neoplasms cholangiocarcinoma gallbladder cancer gallbladder carcinoma gallbladder neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.